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Abstract: UDP-glucose dehydrogenase (UGDH) catalyzes two oxidations of
UDP-glucose to yield UDP-glucuronic acid. Pathological overproduction of
extracellular matrix components may be linked to the availability of UDPglucuronic acid; therefore UGDH is an intriguing therapeutic target. Specific
inhibition of human UGDH requires detailed knowledge of its catalytic mechanism, which has not been characterized. In this report, we have cloned, expressed, and affinity-purified the human enzyme and determined its steady
state kinetic parameters. The human enzyme is active as a hexamer with values for Km and Vmax that agree well with those reported for a bovine homolog.
We used crystal coordinates for Streptococcus pyogenes UGDH in complex
with NAD+ cofactor and UDP-glucose substrate to generate a model of the
enzyme active site. Based on this model, we selected Cys-276 and Lys-279
as likely catalytic residues and converted them to serine and alanine, respectively. Enzymatic activity of C276S and K279A point mutants was not measurable under normal assay conditions. Rate constants measured over several hours demonstrated that K279A continued to turn over, although 250-fold
more slowly than wild type enzyme. C276S, however, performed only a single round of oxidation, indicating that it is essential for the second oxidation.
This result is consistent with the postulated role of Cys-276 as a catalytic residue and supports its position in the reaction mechanism for the human enzyme. Lys-279 is likely to have a role in positioning active site residues and in
maintaining the hexameric quaternary structure.
Abbreviations: UGDH, UDP-glucose dehydrogenase; FPLC, fast protein
liquid chromatography

Introduction
UDP-glucose dehydrogenase (UGDH) catalyzes the conversion
of UDP-glucose to UDP-glucuronic acid, an essential precursor for
synthesis of extracellular matrix polysaccharides in numerous diverse species, including humans. The normal cellular functions of
UGDH have been studied extensively in various organisms by targeted gene disruptions, and these studies demonstrate its importance
in developmental processes. In Drosophila melanogaster, the enzyme is encoded by the sugarless gene and is required for heparan
sulfate modification of proteins that control wing formation (1). In
Caenorhabditis elegans, UGDH fuels the production of glycosaminoglycans essential for vulval morphogenesis and embryonic development (2). In zebrafish, the enzyme is critical for normal cardiac development (3), and the phenotype of targeted disruption is extremely
similar to the murine HAS2 null (4); both phenotypes are lethal. Human and mouse HAS2 proteins are 97% identical and are responsi-

ble for production of hyaluronan at specific developmental stages (5).
Because UGDH provides the requisite UDP-glucuronic acid precursor for hyaluronan synthesis, it is not surprising that UGDH null and
HAS2 null would exhibit similar developmental impairments.
Hyaluronan is an extracellular matrix component that is involved
directly in promoting normal cellular growth and migration, but its
elevated production has been extensively implicated in the progression of epithelial cancers such as breast (6), colon (7), and prostate
(8). Such elevated synthesis of hyaluronan places increased demand
on intracellular UDP-glucuronic acid concentrations, which also
must be increased to compensate. Inhibition of hyaluronan synthesis
recently has been shown to reduce tumor angiogenesis and thereby
restrict in vivo growth of human prostate tumors (9). Restriction of
precursor availability by inhibition of UGDH may regulate the production of hyaluronan in tumors and therefore is a possible novel avenue for therapeutic intervention. Interestingly, UGDH was identified
in breast cancer cells as a gene product dramatically up-regulated in
response to elevated androgen (10), so an androgen-secreting organ
such as the prostate may have a mechanism for increased UGDH expression. Although a clone of human UGDH has been reported (11),
kinetic properties and detailed mechanistic characterization of the purified enzyme (a necessary prelude to inhibitor design) are not available yet.
Kinetic studies of the bovine (12–20), streptococcal (21–24), and
plant (25, 26) enzymes have been reported. All forms of the enzyme
are known to catalyze the same reaction. Two successive oxidations
are performed by the enzyme to convert the 6’-hydroxyl of UDP-glucose to a carboxylate concurrent with reduction of 2 mol of NAD+
to NADH. Early experiments to determine an enzyme mechanism in
the bovine system preceded the availability of sequence information,
so specific catalytic residues were not identified. However, results of
these studies led to the interesting mechanism proposed in Scheme
1 in which we have numbered key residues identified in our experiments. According to analysis of the bovine enzyme, in the first step
the 6’-carbon of UDP-glucose is thought to be covalently attached in
a Schiff base linkage with a lysine residue at the active site of the protein. There is evidence to suggest that this imine undergoes the first
oxidation step yielding an aldimine intermediate that is not released
from the protein. The aldimine is hydrolyzed/attacked by an active
site cysteine to yield a thiohemiacetal that has been detected in both
bovine and streptococcal enzyme systems. This intermediate then is
oxidized a second time to produce a thioester, which is spontaneously
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Experimental Procedures

hydrolyzed to release UDP-glucuronic acid as a product. Hydrolysis of the thioester is thought to be rate-limiting overall. Notably,
the streptococcal enzyme is believed to form a covalent intermediate specifically between the product of the first oxidation and cysteine 260 within the active site, which is required for the second oxidation. This residue is uniformly conserved across all species and
corresponds to cysteine 276 in the human enzyme.
In this report, we have cloned, expressed, and purified recombinant human UGDH. To our knowledge, this is the first characterization of the human enzyme as well as the first mammalian UGDH to
be purified and characterized by site-directed mutagenesis. We have
determined that the enzyme is active as a hexamer with some evidence for assembly in a trimer of dimers as has been proposed for
the bovine enzyme. Steady state kinetic constants were established
and found to be comparable with previously published data in the bovine system. In addition, we generated a structural model of human
UGDH based on the published crystal coordinates for the streptococcal homolog. Using this model and primary sequence alignments of
known UGDH family members, we selected Cys-276 and Lys-279 as
likely active site catalytic residues and converted them to serine and
alanine, respectively. Enzymatic activity of C276S and K279A point
mutants was not measurable under normal assay conditions. Rate
constants were measured over several hours and demonstrated that
K279A continued to turn over, although 250-fold more slowly than
wild type enzyme. C276S, however, performed only a single round
of oxidation indicating that it is essential for the second oxidation.
This result is consistent with the postulated role of Cys-276 as a catalytic residue as shown in Scheme 1 and supports its position in the
reaction mechanism for the human enzyme. Lys-279 appears to function structurally in preserving both the active site architecture and
quaternary structure of the enzyme.

Construction of Expression Vectors for Wild Type UGDH and Point Mutants—Reverse-transcribed poly(A)+ RNA isolated from human prostate tumor cells was used as a template for PCR. Oligonucleotides were designed using the published sequence for human UGDH (Gen-Bank™ accession number
AF061016) to incorporate an NheI restriction enzyme site immediately prior
to the ATG start codon and a SalI site subsequent to the stop codon. The resultant 1.5-kb PCR product was digested with the relevant enzymes and ligated
into similarly digested pET28a, a prokaryotic expression vector incorporating
a cleavable N-terminal His tag (Novagen). Point mutants were generated using the QuikChange site-directed mutagenesis kit (Stratagene) following the
manufacturer’s protocol. Point mutant coding sequences were subcloned in
pET28a. All subclones were sequenced by the Genomics Core at the University of Nebraska-Lincoln.
Expression and Purification of Wild Type and Mutant UGDH—The recombinant plasmids encoding N-terminal His6 fusions to UGDH and the point
mutants C276S and K279A were used to transform Escherichia coli strain
Rosetta(DE3)pLysS (Novagen). Cultures were grown to an A600 of 0.6-0.8 in
2xYT media containing 34 mg/liter chloramphenicol and 30 mg/liter kanamycin at 30 °C and then were induced for 4 h by the addition of isopropyl-1-thioβ-D-galactopyranoside to a final concentration of 0.5 mM. The cells were harvested by centrifugation and resuspended in 50 mM sodium phosphate buffer,
pH 8.0, containing 0.3M NaCl and 10 mM imidazole. Cells were lysed by
sonication and centrifuged for 15 min at 15,000 × g. All three recombinant
proteins were found to be expressed in the soluble fraction. The supernatant
was treated with 0.35% (v/v) polyethyleneimine at 4 °C for 30 min and centrifuged for 15 min at 15,000 × g to separate precipitated nucleic acids from the
protein-containing soluble fraction. The enzyme then was purified by affinity
chromatography using a nickel-chelating column (Novagen) according to the
manufacturer’s protocol. Typical yields were 20-40 mg of purified protein per
liter of bacterial culture. All preparations were >95% pure based upon SDSPAGE (see Figure 1). The purified protein was dialyzed against 20 mM TrisHCl, pH 7.4, and 1 mM dithiothreitol. By comparing uncleaved and thrombincleaved protein in the activity assay described below, we investigated whether
the N-terminal His tag affected wild type enzyme activity. The His tag was
cleaved by incubating the protein with 1 unit/mg thrombin (Novagen) for 1 6
h at 4 °C followed by dialysis against 20 mM Tris-HCl, pH 7.4, and 1 mM dithiothreitol. Cleavage of the tag was verified by SDS-PAGE. Cleaved and uncleaved proteins were found to have identical enzymatic activity. Protein storage conditions also were tested, and the protein, although stable at 4 °C for up
to 48 h, was only stable long-term at –80 °C following flash freezing in a dry
ice/acetone bath. Subsequent characterizations were performed exclusively,
therefore, on aliquots of uncleaved protein stored in this fashion.
Enzymatic Activity Measurement and Kinetic Characterizations—Enzymatic activity of the wild type enzyme was determined by monitoring the
change in absorbance at 340 nm that accompanies the reduction of NAD+ to
NADH. For standard screening of enzymatic activity, the assay was performed
for 30 s at room temperature in 0.1 M Tris-HCl buffer, pH 7.4, containing 1
mM UDP-glucose (Fluka) and 10 mM NAD+ (Sigma). The Km and Vmax for
UDP-glucose and NAD+ were determined independently using standard assay
conditions. Constants for UDP-glucose as substrate were measured by holding NAD+ constant and varying [UDP-glucose] from 0 to 200 μM. Similarly,
NAD+ kinetic measurements were made by holding UDP-glucose constant and
varying NAD+ from 0 to 2 mM. Triplicate values were obtained for each measurement, and data were plotted with Prism software (GraphPad). Km and Vmax
were calculated by fitting the data to the Michaelis-Menten equation and assuming a single binding site each for substrate and cofactor.
Kinetic measurements for the two point mutants initially were made under standard assay conditions, and activity was found to be negligible at the
30-s time point. To determine whether residual enzymatic activity remained
in these mutants, assays were set up with saturating cofactor and substrate,
and an absorbance scan from 290 to 400 nm was collected every 5 min for 4
h. The resulting A340 values then were replotted over the time course of the assay and analyzed in Prism by fitting to a curve with a one-and two-phase exponential rate for C276S and K279A, respectively, to model the first and second oxidations of NAD+.
Determination of Cofactor Binding Constants—To quantify cofactor
binding independently of enzyme activity, intrinsic tryptophan fluorescence
was measured. The wild type protein was scanned to determine the wavelength that gave maximum excitation (290 nm, data not shown); excitation
at this value then was used to scan for maximum emission (335 nm). Each of
the point mutants was scanned to verify equivalent excitation and emission

23592

S O M M E R , B A RY C K I , & S I M P S O N

maxima. Intrinsic tryptophan fluorescence was monitored using these excitation and emission values in the presence of increasing NAD+ from 0 to 1.5
mM. Kd values were obtained for each enzyme by fitting corrected fluorescence quenching to a curve with a single exponential decay (Prism).
Molecular Mass Determination—The functional molecular mass of the
active UGDH enzyme complex was determined by gel filtration chromatography. Purified recombinant UGDH wild type and point mutants were individually loaded on a Superdex 200 HR 10/30 column (Amersham Biosciences)
and separated by FPLC in 50 mM NaPO4, pH 7.0, containing 150 mM NaCl,
at a flow rate of 0.25 ml/min. Size determination was made by comparison
with molecular weight standards (Amersham Biosciences) chromatographed
under the same conditions. The molecular mass standards used (see inset plot
of Figure 3) were as follows: thyroglobulin, 699 kDa; ferritin, 416 kDa; catalase, 219 kDa; aldolase, 176 kDa; albumin, 67 kDa; ovalbumin, 47 kDa; chymotrypsinogen A, 20 kDa; RNase A, 15 kDa. Resolution was sufficient to
calculate molecular masses unambiguously in multiples of 57 kDa (the calculated molecular mass of monomeric His-tagged UGDH).
Homology Modeling and Portrayal of Active Site Residues—Human
UGDH is 23% identical to the Streptococcus pyogenes enzyme for which a
crystal structure has been published. We modeled human UGDH using 3DPSSM (27), which superimposed the human amino acid sequence onto the
Protein Data Bank coordinates for S. pyogenes UGDH (Protein Data Bank
code 1DLI). A ribbon rendering of the model was made with Chimera (28).
The active site was centered upon, and the model, in conjunction with sequence conservation, was used to select appropriate putative catalytic residues, which are depicted in Figure 4.
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Figure 1. Purity of wild type and mutant UGDH. Recombinant His-tagged
human UGDH and specified point mutants were overexpressed in E. coli and
purified to homogeneity from the soluble extract in a single nickel affinity
chromatography step. The purity of wild type UGDH (lane 1), C276S mutant
(lane 2), and K279A mutant (lane 3) proteins was evaluated by SDS-PAGE
followed by staining with GelCode Blue (Pierce). Proteins were judged to be
>95% pure.

Results
Protein Expression and Purification—Although the cDNA for
human UGDH was expressed previously in eukaryotic cells and the
functionality implied by its nomenclature verified, no kinetic data
were reported for the enzyme. Our goal was to measure steady state
kinetic constants for wild type human UGDH, determine the subunit
structure of the active enzyme complex, identify key active site residues, and assess the role of each in the enzyme mechanism. To facilitate these characterizations, wild type UGDH and specific point
mutants each were subcloned in a bacterial expression vector that encoded an N-terminal 6-histidine fusion for affinity purification. The
resultant constructs expressed abundant soluble recombinant UGDH
in E. coli, and each enzyme form was purified to homogeneity by
nickel affinity chromatography (Figure 1). To verify that the N-terminal histidine tag did not affect the structure or function of wild
type UGDH or its mutants, the histidine tag was removed by thrombin cleavage, and the resulting protein was compared with uncleaved
protein. Because cleaved and uncleaved proteins exhibited identical
levels of enzyme activity (data not shown), uncleaved protein was
used for subsequent characterizations.
Kinetic Characterization of UGDH—UGDH catalyzes conversion of a UDP-glucose substrate to a UDP-glucuronic acid product,
concomitantly reducing two molecules of NAD+ to NADH. The enzymatic activity of wild type UGDH was characterized by steady
state kinetic analysis. To obtain kinetic constants (Km and Vmax) for
substrate and cofactor, we measured the steady state level of NADH
by its absorbance at 340 nm. Measurements to determine the dependence of the reaction on cofactor concentration were conducted using
purified UGDH incubated with increasing concentrations of NAD+ in
the presence of saturating UDP-glucose substrate (Figure 2A). Similarly, dependence of reaction kinetics on substrate was measured by
increasing UDP-glucose concentration in the presence of saturating
NAD+ (Figure 2B). Saturation kinetics were observed for both conditions. Data were fitted to the Michaelis-Menten equation to obtain
Km and Vmax for the reaction catalyzed by the wild type enzyme (Table I). Both sets of conditions yielded a similar Vmax of ≈120 nmol of
NAD+/min/mg of enzyme. The Km for UDP-glucose was 11.2 μM,
and the Km for NAD+ was 355 μM.

Figure 2. Wild type UGDH demonstrates saturable kinetics for NAD+
(A) and UDP-glucose (B). Steady state enzyme activity was measured as
conversion of NAD+ to NADH detected by absorbance at 340 nm. Purified
human UGDH (0.5 mg/ml in 0.1 M Tris-HCl, pH 7.4) was incubated for 1
min with increasing concentrations of NAD+ (0-2 mM) in the presence of saturating substrate (A, UDP-glucose, 2 mM) or with increasing concentrations
of UDP-glucose in the presence of saturating cofactor (B, NAD+, 2 mM).

Characterization of UGDH Oligomeric State—Previous studies with S. pyogenes UGDH indicate that the enzyme is a dimer, but
the bovine enzyme is considered to be hexameric. To determine the
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Table I
Steady state kinetic constants for wild type UGDH

oligomeric state of human UGDH, we performed size exclusion analysis by FPLC (Figure 3). Consistent with data for the bovine ortholog, human UGDH predominantly is observed as a hexamer eluting
from the gel filtration column at a molecular mass corresponding to
six times the single subunit mass (peak I). Significant dimeric (II)
and monomeric (III) species also are present, indicating some subunit dissociation. This elution profile was observed repeatedly over
several different preparations of the enzyme with relative species ratios conserved so the distribution of subunit structures appears to be
an innate property of the enzyme. The inset panel shows molecular weight determination for the peaks on the basis of size exclusion
standards. The functional enzyme was analyzed independently by dynamic light scattering (data not shown), which estimated its molecular mass at 345 kDa (hydrodynamic radius of 7.2 nm) consistent with
a hexameric assembly of the 57-kDa monomers.
Determination of UGDH Cofactor Binding Affinity—To characterize the initial binding of NAD+ cofactor to UGDH independently
of its apparent binding during 2-fold oxidation in turnover, we monitored the intrinsic tryptophan fluorescence of UGDH. We determined
that fluorescence emission of the protein at 335 nm was quenched
by the incremental addition of NAD+ (data not shown). Tryptophan
quenching was plotted as a function of NAD+ concentration and fitted to an exponential decay assuming a single binding site (Prism).
The resulting dissociation constant was 118 ± 3.3 μM (Table II). This
value is comparable in order of magnitude to the Km for NAD+ determined by catalytic turnover.
Homology Modeling of UGDH—The structure for human UGDH
has not been solved yet, but the human enzyme is 23% identical to its
ortholog in S. pyogenes for which a structure was recently published.
Using the coordinates of the bacterial enzyme complexed with cofactor and substrate, we modeled the human enzyme as a ternary complex with NAD+ cofactor and UDP-glucose substrate and inspected
the architecture of the active site (Figure 4). The degree of structural
similarity was sufficient to identify specific residues in the human enzyme likely to participate in catalysis. Cys-260 of the streptococcal
UGDH was mutagenized previously and found to reduce enzyme activity. Based on the homology model of human UGDH and previously published studies of the bacterial enzyme, we identified specific residues within the active site that were likely to be important
for catalytic activity. We generated point mutations at residues Cys276 (the human analog of Cys-260) and Lys-279 to investigate their
individual contributions to the enzyme mechanism. Figure 4 illustrates the position of these two residues in the active site of the human UGDH model relative to NAD+ and UDP-glucose. Also shown
are side chains of residues Lys-220 and Asp-280 (see “Discussion”).
Kinetic Characterization of UGDH Point Mutants—Catalytic activity of UGDH point mutants C276S and K279A initially was measured under standard reaction conditions and found to be negligible.
For C276S, this observation is consistent with results of the analogous C260S streptococcal point mutant, which lacked activity to an
unquantified degree. To evaluate the role of each residue in catalysis and determine the extent of impaired catalytic function, we performed a time course over 4 h, measuring enzyme activity every 5
min by absorbance wavelength scans from 290 to 400 nm. Conver-

sion of NAD+ to NADH by C276S (Figure 5A) was found to saturate
at a concentration equimolar to that of added protein, suggesting that
a single round of oxidation can occur in the absence of this cysteine
but that the cysteine is essential for the second oxidation. In contrast,
cofactor reduction was not saturable in the reaction catalyzed by the
K279A mutant (Figure 5B), demonstrating its continued capacity for
multiple turnover.
Absorbance values at 340 nm were replotted as a function of assay time to determine kinetic constants for the reaction (Figure 5C).
As mentioned above, values for C276S were observed to plateau at
an A340 of ≈0.17. This absorbance value corresponds to a 1:1 molar
ratio of NADH produced relative to added protein. Under identical
conditions, K279A continued to turn over without reaching an end
point.
Saturable C276S kinetic data were fitted to an equation with a
single rate for catalysis of ≈2.7 nmol of NAD+/min/mg of enzyme
(Table III). This value is ~50-fold diminished from the overall rate of
NAD+ turnover by wild type enzyme. Cys-276 therefore is not only
essential for the second round of oxidation; it is also involved in efficient execution of the first round. Data replotted for K279A, which
did not achieve saturation in the time course of the assay, revealed
two rate constants. The first, k1, was comparable with the rate constant for C276S (≈2.5 nmol/min/mg), but was followed by a much
slower rate, k2, of ≈0.4 nmol/min/mg. Hence, although not directly
required for either oxidation, Lys-279 appears to have a global role in
the catalytic function.
Cofactor Binding by Wild Type and Mutant UGDH—To verify
that observed differences in enzyme activity among wild type and
point mutants of UGDH were not attributable to a loss of cofactor
binding, we compared intrinsic tryptophan quenching in the presence
of increasing concentrations of NAD+. Fluorescence emission was
fitted to a saturation curve assuming a single binding site. Resultant
dissociation constants (Table II) demonstrate comparable cofactor affinities among wild type and mutant UGDH (118, 127, and 103 μM
for wild type, C276S, and K279A, respectively), suggesting that the
folded structures of the mutant proteins were unaffected by the respective point mutation. Furthermore, loss of enzymatic activity was
not the result of a change in binding of NAD+ by either mutant despite the suggestive hydrogen bonding proximities illustrated by Figure 4 that might implicate Lys-279 in cofactor binding.
Subunit Association of Mutant UGDH—Because altered catalytic activity of the mutants also could result from changes in quaternary structure, the oligomeric state of the mutant enzymes was examined for perturbations by size exclusion FPLC. Whereas C276S
retained a predominantly hexameric structure with a minor dimeric
peak as compared by overlay of its elution profile on that of the wild
type enzyme (Figure 6A), K279A is found almost exclusively as a dimer (Figure 6B). This observation is consistent with the UGDH quaternary structure adopting a “trimer of dimers” arrangement within
the hexameric protein. Although the homology model of UGDH does
not predict a surface exposed location for Lys-279, it appears to be
required for maintenance of the trimer interfaces that must occur independently of dimerization.
Discussion
UGDH is expressed by most species from bacteria to humans.
In plants and bacteria, its role is in the maintenance of structural integrity. In animals, its functional significance is developmental, and
its dysregulation is linked indirectly to several pathologies, including
cancer progression. Specific targeted inhibition of this enzyme may
offer a therapeutic avenue but requires a detailed understanding of its

23594

S O M M E R , B A RY C K I , & S I M P S O N

IN

JOURNAL

OF

B I O L O G I C A L C H E M I S T RY 279 (2004)

Figure 3. Wild type UGDH is active as a hexamer.
Purified human UGDH was fractionated by gel filtration FPLC on a Superdex 200 HR 10/30 resin. One
major and two minor peaks were detected as discussed in the text. Size determination was made by
comparison with molecular weight standards fractionated under identical conditions. Average retention time in the column was plotted versus the log of
the molecular weight for each standard (inset). Standards used were as follows: thyroglobulin, 699 kDa;
ferritin, 416 kDa; catalase, 219 kDa; aldolase, 176
kDa; albumin, 67 kDa; ovalbumin, 47 kDa; chymotrypsinogen A, 20 kDa; RNase A, 15 kDa.

Table II
NAD+ binding constants for wild type and mutant UGDH

Figure 4. Active site model of the UGDH ternary complex. The human
UGDH primary sequence was superimposed on the published crystal structure coordinates for the S. pyogenes enzyme (Protein Data Bank code 1DLI).
A model was generated using 3D-PSSM and was represented in Chimera as
a ribbon diagram. The model depicts the human enzyme in complex with
NAD+ cofactor and UDP-glucose substrate. Side chains of specific active site
residues discussed in the text are shown. The network of hydrogen bonding
between protein active site residues and the cofactor and substrate is illustrated by dotted lines (see “Discussion”). The coloring scheme is as follows:
the overall helical ribbon is blue and the loops are yellow; within the active
site, carbon atoms of the protein are gray, carbons in the cofactor and substrate are green, nitrogen is blue, oxygen is red, sulfur is yellow, and phosphorus is pink.

mechanism. To date, most mechanistic studies have focused on the
bovine or bacterial forms of the enzyme. In the study we have presented here, human UGDH was cloned, expressed, and purified to
homogeneity. We report the first characterization of its mechanistic
features. Kinetic properties of the hexameric enzyme are comparable

with those reported previously for UGDH orthologs. Specific point
mutants were generated based on homology modeling of the enzyme
and used to dissect the components of the enzyme reaction sequence.
Cys-276 is required for the second but not the first of the two successive oxidations. Lys-279 is not an absolute requirement for activity,
but mutation of this residue impairs catalysis and disrupts the quaternary structure of the protein. Its role probably is to position the active
site cysteine for maximally efficient catalysis, but it may also be an
important contact at the trimeric interface.
Human UGDH is closely related to the enzyme characterized
from bovine liver but is only 23% identical to the S. pyogenes enzyme, both of which catalyze the same 2-fold oxidation of UDP-glucose to UDP-glucuronic acid, apparently by similar mechanisms. Not
surprisingly, the kinetic activity and quaternary structure of the wild
type human protein are very similar to the bovine; the kinetic constants we have measured are within 2-fold of those reported for the
bovine enzyme, which also functions as a hexamer (16). The S. pyogenes enzyme, in contrast, is dimeric and has slightly lower binding
constants for substrate and cofactor relative to both mammalian proteins (23). It is not clear what role subunit associations may play in
enzyme function. Both substrate binding assays and chemical modifications of the active site cysteines in the bovine enzyme suggest
that there is half-site reactivity among the subunits in the trimer of dimers that is induced through subunit communication following the
first binding event (17, 20). This phenomenon may provide a regulatory mode for human and bovine UGDH. Although it is possible that
the reduced activity of our K279A mutant is attributable to its altered
subunit structure, we have additionally generated a point mutant,
K339A, that also is dimeric but exhibits activity comparable with
that of wild type (data not shown). Lys-279 is shown by the homology model to be located in a solvent-exposed stretch of helix adjacent
to the dimerization interface. Evolutionarily speaking, the hypothesis has been put forth that the bacterial enzyme preceded the animal
forms (11). The dimer interface then most likely would be conserved
among species, and the contacts between dimers would be elsewhere.
The quaternary structures of our lysine mutants are consistent with
conserved localization of the dimer interface and predict that interdimer association occurs through contacts maintained, at least in part,
by the solvent-exposed helix containing Lys-279.
Site-directed mutagenesis is a powerful tool with which to functionally dissect the roles of residues within an enzyme active site. To
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Figure 6. Size determination of UGDH point mutant structures. Molecular mass of the functional point mutant enzyme complexes was measured
by FPLC as described under “Experimental Procedures” and in the legend
to Figure 3. A, C276S superimposes on the wild type trace and is likely hexameric. B, K279A superimposes on the wild type dimer, indicating that this
mutant is functioning predominantly as a dimer in kinetic assays.

Figure. 5. Kinetic comparison of UGDH point mutants. Purified recombinant UGDH point mutant enzyme activity was assayed as conversion of
NAD+ to NADH detected by absorbance scans from 290 to 400 nm. Standard
conditions used for wild type enzyme produced no activity from the mutant
enzymes, so a time course was performed. A, C276S scans at 5-min intervals
to 4 h. B, K279A scans at similar time points. C, absorbance at 340 nm was
replotted over the time course of the assay to compare NADH appearance for
C276S (solid line) and K279A (dotted line).
Table III
Rate constants for wild type and mutant UGDH

date, only one such study has been done; cysteine 260 of S. pyogenes
UGDH was converted to a serine, and the mutant lost activity but
no quantitative data were published (24). Active site residues in the
bovine enzyme have been identified by chemical modifications only.
We sought to acquire mechanistic details for the human enzyme by
a combination of site-directed mutagenesis, activity measurements,
and homology modeling. Although only 23% identical to bacterial
UGDH, the sequence of the human enzyme mapped well onto the
crystal coordinates determined for the bacterial enzyme. By modeling the protein in this fashion, we were able to generate an image
of the putative interactions within the active site of a ternary complex composed of human UGDH, NAD+ cofactor, and UDP-glucose
substrate (Figure 4). Inspection of this model, combined with identification of conserved residues in a primary sequence alignment of
UGDH across diverse species and consideration of published data for
the bovine and bacterial enzymes, directed us toward the selection
of two key conserved amino acid residues likely to have a role in the
catalytic mechanism: Cys-276 and Lys-279.
The figure illustrates a network of hydrogen bonding interactions
within the active site that may serve to stabilize the ternary complex
and facilitate catalysis. Lys-279 appears to bind the 3’-hydroxyl of
the NAD+ ribose (though mutation of that residue had no effect on
our NAD+ binding data) and forms an electrostatic interaction with
Asp-280. Asp-280, in turn, positions a water molecule at the active
site, thereby indirectly linking to NAD+, the 6’-OH of the substrate,
and Cys-276. This water molecule may be a structural edifice or a
component of the reaction mechanism. It has been suggested that the
water molecule would serve as a general base for proton abstraction
during the first oxidation step in the bacterial reaction scheme (23).
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Its central location at the active site then would be important to preserve and would depend on interactions donated by Lys-279 and Cys276, but our data do not address this directly. The cysteine thiol thus
positioned is within hydrogen bonding distance of the 6’-hydroxyl of
UDP-glucose and is located appropriately for catalysis.
The mechanism proposed for bacterial UGDH involves the production of UDP-hexodialdose as an intermediate (21). Catalysis then
is postulated to proceed via formation of a thiohemiacetal between
Cys-276 and this intermediate, which is oxidized to a thioester before
hydrolysis to yield the final carboxylate product. Our data demonstrate that Cys-276 is capable of a single NAD+ reduction, which is
consistent with this hypothesis. However, the hexodialdose intermediate never has been isolated either from the bacterial or the bovine
reaction system. Instead, investigators of the bovine system postulated a reaction intermediate that was covalently linked to the enzyme
and not released between oxidations (14). Ordman and Kirkwood
(14) hypothesized a Schiff base intermediate that would be linked
via an active site lysine. To demonstrate this and identify the enzyme
residue linkage, these authors derivatized the putative active lysine
with [14C]formaldehyde and reduced with NaBH4, thereby placing a
mechanism-dependent label at the active site. These studies clearly
suggest that the enzyme first forms a Schiff base linkage with the 6’carbon of UDP-glucose, allowing the C-6’-hydroxyl subsequently to
undergo the first oxidation, as we have depicted in Scheme 1. Our
data using C276S also are consistent with this scheme. Interestingly,
although Lys-279 appeared to be important for maximally efficient
catalysis, its role is probably indirect: to constrain the position of an
essential catalytic residue or the active site water. Accordingly, we
have mutagenized an additional lysine, K220A, which entirely lacks
enzymatic activity, implying that Lys-220 is an essential catalyst for
the first oxidation of UDP-glucose and highlighting it as a candidate
for the Schiff base intermediate. (B. J. Sommer, J. J. Barycki, and M.
A. Simpson, manuscript in preparation.)
The collective summary of the studies described suggests to
us the reaction mechanism as outlined in Scheme 1 with key residues we have identified illustrated in their respective roles. The reaction sequence is initiated by the binding of UDP-glucose, followed
by NAD+. Lys-220 forms a covalent linkage to the C-6’ of UDP-glucose, the hydroxyl is lost as water, and the secondary amine is oxidized to a Schiff base between C-6’ and Lys-220, releasing NADH.
The thiol of Cys-276 simultaneously attacks C-6’ as water hydrolyzes the Schiff base, forming a thiohemiacetal that is oxidized by reduction of a second NAD+ to the thioester. Hydrolysis of the thioester releases the final UDP-glucuronic acid product. The mechanism
suggests that specific inhibitors may be most effective at the level of
Schiff base or thiohemiacetal formation because these would exploit
the retention of covalent intermediates by the enzyme and be mechanistic inhibitors.
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